首页> 外文期刊>Virology >Prior DNA immunization enhances immune response to dominant and subdominant viral epitopes induced by a fowlpox-based SIVmac vaccine in long-term slow-progressor macaques infected with SIVmac251
【24h】

Prior DNA immunization enhances immune response to dominant and subdominant viral epitopes induced by a fowlpox-based SIVmac vaccine in long-term slow-progressor macaques infected with SIVmac251

机译:先前的DNA免疫增强了感染SIVmac251的长期慢进猕猴对基于禽痘的SIVmac疫苗诱导的显性和次要病毒表位的免疫反应

获取原文
获取原文并翻译 | 示例
       

摘要

A therapeutic vaccine for individuals infected with HIV-1 and treated with antiretroviral therapy (ART) should be able to replenish virus-specific CD4+ T-cells and broaden the virus-specific CD8+ T-cell response in order to maintain CD8+ T-cell function and minimize viral immune escape after ART cessation. Because a combination of DNA and recombinant poxvirus vaccine modalities induces high levels of virus-specific CD4+ T-cell response and broadens the cytolytic activity in naive macaques, we investigated whether the same results could be obtained in SIVmac251-infected macaques. The macaques studied here were long-term nonprogressors that naturally contained viremia but were nevertheless treated with a combination of antiviral drugs to assess more carefully the effect of vaccination in the context of ART. The combination of a DNA expressing the gag and pol genes (DNA-SIV-gp) of SIVmac239 followed by a recombinant fowlpox expressing the same SIVmac genes (FP-SIV-gp) was significantly more immunogenic than two immunizations of FP-SIV-gp in SIVmac251-infected macaques treated with ART. The DNA/FP combination significantly expanded and broadened Gag-specific T-cell responses measured by tetramer staining, ELISPOT, and intracellular cytokine staining and measurement of ex vivo cytolytic function. Importantly, the combination of these vaccine modalities also induced a sizeable expansion in most macaques of Gag-specific CD8-(CD4+) T-cells able to produce TNF-α, Hopefully, this modality of vaccine combination may be useful in the clinical management of HIV-1-infected individuals.
机译:针对感染HIV-1并接受抗逆转录病毒疗法(ART)治疗的个体的治疗性疫苗应能够补充病毒特异性CD4 + T细胞并扩大病毒特异性CD8 + T细胞反应,从而维持CD8 + T细胞功能并在停药后将病毒免疫逃逸降至最低。因为DNA和重组痘病毒疫苗形式的组合可诱导高水平的病毒特异性CD4 + T细胞反应并扩大幼稚猕猴的溶细胞活性,所以我们调查了在SIVmac251感染的猕猴中是否可以获得相同的结果。此处研究的猕猴是长期非进展的,其自然含有病毒血症,但仍接受抗病毒药物的组合治疗,以更仔细地评估抗病毒药物在ART中的效果。表达SIVmac239的gag和pol基因的DNA(DNA-SIV-gp)与随后表达相同SIVmac基因的重组鸡痘(FP-SIV-gp)的组合比两次免疫FP-SIV-gp的免疫原性明显更高接受ART治疗的SIVmac251感染猕猴通过四聚体染色,ELISPOT和细胞内细胞因子染色以及离体溶细胞功能的测定,DNA / FP组合显着扩展了加宽的Gag特异性T细胞反应。重要的是,这些疫苗形式的组合还诱导了大多数猕猴中能够产生TNF-α的Gag特异性CD8-(CD4 +)T细胞的大规模扩增。希望这种疫苗组合形式可用于临床治疗感染HIV-1的个体。

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号